This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello, everyone, and welcome to this Medscape InDiscussion podcast. Today we're talking about chronic thromboembolic pulmonary ...

Pulmonary embolism (PE) is caused by emboli, which have originated from venous thrombi, travelling to and occluding the arteries of the lung. PE is the most dangerous form of venous thromboembolism, ...

SCINTILLATION scanning of the lungs is being used with increasing frequency as a means of establishing the diagnosis of pulmonary thromboembolism. 1–6 Little information is available, however, ...

The Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program is dedicating to identifying, diagnosing, and treating patients with CTEPH disease. Because many people with chronic thromboembolic ...

Bayer's Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension Submitted For Regulatory Approval in the U.S. and EU Riociguat is the first drug ...

Pulmonary hypertension (PH) is a rare group of serious but LOCALIZED medical conditions that can have full-body impacts if ...

A 42-year-old man, a resident of Afghanistan, presented with intermittent episodes of mild hemoptysis and dyspnea on exertion for the past 6 months, for which he did not undergo any diagnostic test.

Hilary M. DuBrock, MD: Chronic thromboembolic pulmonary hypertension [CTEPH] is Group 4 PH [pulmonary hypertension]. These patients have pulmonary hypertension that develops due to chronic thrombi and ...

Bayer's Xarelto® (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism (PE) and the Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE in the EU Blood clots obstructing blood flow in ...